{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-26-000003","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2026-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.941767+00:00","generated_at":"2026-05-16T10:25:18.993685+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AbCellera doses first patients in Phase 2 trial of ABCL635 for menopausal vasomotor symptoms","bullets":["ABCL635, a non-hormonal candidate for moderate-to-severe vasomotor symptoms (VMS) of menopause, advances to Phase 2.","Phase 2 is a randomized, double-blind, placebo-controlled study in 80 postmenopausal women.","Top-line clinical results for both Phase 1 and Phase 2 expected in Q3 2026.","Phase 1/2 redesignation based on interim safety, tolerability, and pharmacodynamic data from healthy volunteers."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-26-000003","json":"https://secwatch.observer/filing/0001703057-26-000003.json","markdown":"https://secwatch.observer/filing/0001703057-26-000003.md","text":"https://secwatch.observer/filing/0001703057-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000003/0001703057-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000003/abcl-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:25:18.993685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}